| Pair Name | Ginsenoside Rg3, Doxorubicin | ||
| Phytochemical Name | Ginsenoside Rg3 (PubChem CID: 9918693 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Ginsenoside Rg3, Doxorubicin | |||
| Disease Info | [ICD-11: 2B51] | Osteosarcoma | Investigative | |
| Biological Phenomena | Inhibition-->Angiogenesis | |||
| In Vitro Model | 143B | Osteosarcoma | Homo sapiens (Human) | CVCL_2270 |
| U2OS | Osteosarcoma | Homo sapiens (Human) | CVCL_0042 | |
| In Vivo Model | Ginsenoside Rg3 combined with doxorubicin inhibits tumour growth and lung metastasis in 143B-derived murine osteosarcoma models. | |||
| Result | We concluded that the combination of ginsenoside Rg3 and doxorubicin displayed an evidently synergistic effect, which has the potential to be used as an effective and safe therapeutic approach for OS treatment. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. J Pharm Pharmacol. 2023 Nov 23;75(11):1405-1417. doi: 10.1093/jpp/rgad070. | Click |
